The company stated today that its experimental treatment for an inherited blood disorder met the main goal in a late-stage study.
The U.S. health regulator’s staff reviewers raised concerns related to interpretation of results from trials for Lykos Therapeutics psychedelic drug MDMA to treat post-traumatic stress disorder.
After winning approval earlier this month in follicular lymphoma, Bristol Myers Squibb’s Breyanzi got the FDA nod for another indication on Thursday: relapsed or refractory mantle cell lymphoma (MCL). Find out what other FDA approvals have recently gone through.
The American Society of Clinical Oncology annual meeting kicks off today in Chicago, with highly anticipated presentations that include reports on a bispecific antibody, an ADC and a BCMA-targeted CAR-T cell therapy.
The company said patients with a type of leukemia who took its Scemblix had a significantly better response and a lower dropout rate than those who received current standard-of-care drugs in a late-stage study with details presented today.
Pfizer said it expects its cancer drug Lorbrena to top $1 billion in annual sales by 2030 on the strength of data presented on Friday showing most patients treated for a rare form of advanced lung cancer in a clinical trial were alive without the disease worsening after five years.